In order to make the surface antigen of hepatitis B virus turn negative, many hepatitis B patients change their medication without authorization or even believe in false medical advertisements. Patients with hepatitis B should set the right treatment goals, unrealistic and eager to achieve will affect the effectiveness of treatment. The international medical community has an analogy for the goal of antiviral treatment for chronic hepatitis B: a negative hepatitis B virus DNA is a “bronze medal”, a negative hepatitis B virus e antigen with the possibility of antibodies is a “silver medal”, and a negative hepatitis B virus surface antigen is a “Gold”. Hepatitis B treatment is very difficult to pick the “gold”, only about 0.1% to 1% of patients may have the virus surface antigen turned negative. Therefore, in 2005, China issued the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B”, which proposed that the overall goal of treatment is “maximum long-term suppression or elimination of the hepatitis B virus”, rather than the conversion of hepatitis B surface antigen. At present, hepatitis B is not completely cured, but due to the multiple pressures and the desire to return to normal life and work, many patients are eager to pursue “turning negative” instead of adhering to treatment, stopping or changing medication without authorization, or even believing in advertisements. Surveys show that 25% of patients can only afford 1 year of antiviral treatment. Believing in false advertisements is likely to delay the disease, while stopping and changing medication without permission is likely to lead to recurrent disease and drug resistance, which is the main obstacle to achieving long-term treatment goals for hepatitis B. Patients with hepatitis B should establish rational long-term treatment goals, base on the long term, and pay attention to primary treatment. “The timing of primary treatment is very important for the treatment of chronic hepatitis B. If treated with nucleoside analogs, it is best to choose a regimen with potent viral suppression and a low resistance rate from the beginning.” He described that the nucleoside analog with the lowest resistance rate is entecavir, with a 5-year cumulative resistance rate of 1.2 percent, which is why it is recommended as a first-line drug in both European and American and Chinese guidelines for prevention and treatment. In addition, data from a recent clinical trial presented at the Asia-Pacific Hepatology Annual Meeting showed that chronic hepatitis B patients treated with entecavir for 7 to 7 years could sustainably inhibit hepatitis B virus replication and also significantly reduce liver inflammation and reverse liver fibrosis and cirrhosis. However, he also pointed out that the choice of antiviral drugs also depends on the individual patient’s situation and affordability, etc. Nucleoside analogues are not recommended for young people of childbearing age or for patients with recent pregnancy plans, as they are difficult to stop in the short term.